Pharmaceutical & Medical Device Risk-Sharing & Value-Based Pricing & Reimbursement Schemes

Event Overview

There is clearly an increasing need for more innovative pricing and reimbursement agreements to help to balance the (often) conflicting objectives of pharmaceutical and medical technology manufacturers, payers, health technology assessors (HTA), physicians and patients.

There is a sustained increase in the cost of healthcare and ever-increasing range of expensive drugs and technologies available as potential therapies. Clearly, difficult choices need to be made by HTAs about which products receive funding from increasingly restricted healthcare budgets, especially with often insufficient clinical and real-life evidence available.

In terms of innovative agreements, risk-sharing and value-based models (for example) are being proposed more often by more manufacturers, in more countries. Such agreements are increasingly being seen as a method in which pharma and medical device companies can obtain HTA approval to finance the drug from limited budgets, but also a strategy to gain a competitive advantage and preferential market access.

Both life sciences companies and policy-makers are looking to achieve a clearer picture of how risk-sharing and value-based agreements can and do work effectively in the real-world. Many complex agreements exist in various countries, whilst some governments and pharma companies in other markets may alternatively have less experience with such models.

Many stakeholders need answers to important questions such as: "What is the definition of risk-sharing and value-based pricing models? Are such models necessary? What are the alternatives? What successful models exist? How can clear endpoints and goals be defined? How can we measure performance effectively? And how different models are being viewed by different stakeholders? Can risk-sharing and value-based agreements bring a competitive advantage to pharma companies?"

Why Attend?

• Appreciate how the US approach to conditional reimbursement differs from Europe and other global markets: what can be learnt, implemented, and what will and won’t work
• Understand the opportunities, obstacles and challenges in designing and implementing innovative agreements
• Find out when risk-sharing agreements are required and how they can be designed to satisfy all stakeholders to gain market access
• Understand whether or not the turbulent macroeconomic environment and President Obama’s planned healthcare reforms will increase payer motivation for flexible agreements
• Benchmark, network and co-operate with policy makers and key influencing figures
• Obtain the best and most focused picture of risk-sharing and value-based pricing models today
• Learn how drug effectiveness is being demonstrated in different regions
• Understand the best ways to communicate value and achieve maximum patient and market access
• Hear the perspectives of all stakeholder groups: Government, HTA agencies, insurers, doctors, health economists and the pharmaceutical industry
• Discover how payers are evaluating conditional reimbursement agreements

Who Should Attend?

Pharmaceutical companies: Vice-Presidents, Directors, Managers involved in:Pricing & Reimbursement, Health Economics & Outcomes,Government, Payer & Stakeholder Relations, Regulatory Affairs, Medical Affairs, Marketing, Therapy Area Heads, Market Access, Country Managers, Managed & Specialized Care, HMO Managers

Solution providers consultants: CEOs, Business Development, senior Consultants, Partners, Regional Heads.

Independent Academics, Health Economists, Senior Doctors, & Patient Representatives.

Prestigious Speaker Panel

A more detailed list of speakers’ names is available on the downloadable agenda. Please „request event agenda“ below. 

Contact Details

NextLevel Pharma
Phone: +421 232 662 621
Fax: +421 232 662 622
Email: marketaccess(at)nextlevelpharma.com